Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis

Patients with autoimmune pulmonary alveolar proteinosis received inhaled molgramostim or matching placebo for 24 weeks. Patients receiving molgramostim had greater improvement in pulmonary gas transfer and alleviation of symptoms than those receiving placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-10, Vol.383 (17), p.1635-1644
Hauptverfasser:	Trapnell, Bruce C, Inoue, Yoshikazu, Bonella, Francesco, Morgan, Cliff, Jouneau, Stéphane, Bendstrup, Elisabeth, Campo, Ilaria, Papiris, Spyros A, Yamaguchi, Etsuro, Cetinkaya, Erdogan, Ilkovich, Mikhail M, Kramer, Mordechai R, Veltkamp, Marcel, Kreuter, Michael, Baba, Tomohisa, Ganslandt, Cecilia, Tarnow, Inge, Waterer, Grant, Jouhikainen, Taneli
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Adult Alveoli Autoimmune Diseases - drug therapy Autoimmune Diseases - physiopathology Autoimmune Diseases - therapy Biomarkers Blood pressure Bronchoalveolar Lavage Colony-stimulating factor Disease Double-Blind Method Drug Administration Schedule Exercise Tolerance FDA approval Female General & Internal Medicine Granulocyte-macrophage colony-stimulating factor Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects Health Status Humans Hypoxemia Inhalation Lavage Life Sciences Life Sciences & Biomedicine Male Medicine, General & Internal Middle Aged Oxygen - blood Pathogenesis Pulmonary Alveolar Proteinosis - drug therapy Pulmonary Alveolar Proteinosis - physiopathology Pulmonary Alveolar Proteinosis - therapy Pulmonary Gas Exchange Rare diseases Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Science & Technology Sediments Statistical analysis Surfactants Walk Test
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with autoimmune pulmonary alveolar proteinosis received inhaled molgramostim or matching placebo for 24 weeks. Patients receiving molgramostim had greater improvement in pulmonary gas transfer and alleviation of symptoms than those receiving placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1913590